Insitu Biologics continues to make rapid progress towards our mission of providing patients and physicians with an opioid-free solution for post-operative pain. We have added exceptional talent […]
Insitu Biologics continues to make rapid progress towards our mission of providing patients and physicians with an opioid-free solution for post-operative pain. We have added exceptional talent […]
We have received a tremendous amount of interest in this last tier and have also received requests to hold the offering open longer to allow numerous interested […]
Our Biotech Investor Presentation is TONIGHT! As our Regulation A+ offering is coming to a close, we invite you to join us for an investor presentation […]
The Financial Opportunity As many of you know, post-operative pain treatment is dominated by opiates, with 95% of patients receiving opiates for pain management. Only one non-opioid, […]
InSitu Biologics’ co-founder and medical adviser Dan Sipple has been featured by his alma mater Des Moines University. Click here to read the article: http://bit.ly/DMUFeature
As of October 19th, our Stock Offering is once again open and accepting investments. Our plan is to close our Regulation A+ Offering for the last time […]
As of October 15, our Stock Offering is temporarily paused. During this pause, we will be taking reservations and encourage prospective investors to reserve shares via the […]
Thank you to LGM Pharma for including InSitu Biologics in a recent Client Feature! We have recently shifted management of our supply chain to LGM Pharma, including […]
InSitu Biologics Announces New Leadership InSitu Biologics today announced that its Board of Directors has appointed Kevin Bassett as President and Chief Executive Officer and member of […]
Tier 4 of the offering has officially closed and we have qualification from the SEC to sell our shares at the price of $8.20 per share. We […]